

# INNOVATIVE MEDICINES ARE ESSENTIAL TO THE CANADIAN KNOWLEDGE-BASED ECONOMY AND FOR THE BETTER HEALTH OF ALL CANADIANS

---



INNOVATIVE  
MEDICINES  
CANADA



**\$19B**

in economic activity



**30,000**

high-value jobs



**10%**

of revenues<sup>2</sup> invested  
into R&D

Innovative medicines and vaccines  
help prevent and cure disease.

# \$19B in economic activity

**As one of Canada's leading innovative sectors, Innovative Medicines Canada member companies make significant contributions to the country's economy.**

Generating \$19 billion in economic activity, Innovative Medicine's Canada's members play an important role in Canada's health sector, life sciences ecosystem and broader economy, and through the purchasing power of its employees.



# 30,000 high-value jobs

**The activities of Innovative Medicines Canada's members support over 30,000 high-value jobs across the Canadian economy.**

The Canadian life sciences sector attracts top-tier researchers and physicians, and compares favourably to other industry sectors in Canada. In addition, Innovative Medicines Canada's members contribute both directly and indirectly to employment through a network of supply chains and distribution activities.



# 10% of revenues<sup>2</sup> invested into R&D

**Innovative Medicines Canada member companies invest \$1.2 billion annually into research and development, stimulating innovation and creating life-changing and life-saving medicines for Canadians.**

Out of 100 top corporate spenders, the life sciences sector ranks 3<sup>rd</sup> in terms of combined total R&D spending in Canada, ahead of the natural resources and auto industry sectors and behind only aerospace and software/computer services. Primarily clinical research-based activities, these investments<sup>1</sup> include randomized controlled trials and real-world evidence studies.

The inclusion of additional investments in innovation include university chair endowments, research grants, and investment in life sciences superclusters and biotechs, round out members' total contributions to R&D and innovation to an estimated total of 10%.<sup>2</sup>



ERNST & YOUNG, INNOVATIVE MEDICINES CANADA DATA ANALYTICS AND MEMBERS' ECONOMIC FOOTPRINT AND IMPACT IN CANADA, SEPTEMBER 2017

<sup>1</sup> These investments include PMPRB Form 3 SRED-eligible and non-SRED-eligible R&D, as well as investments in randomized controlled trials (RCT), real world evidence (RWE), and Phase IV studies.

<sup>2</sup> 9.97% of gross patented product revenues reported in 2016 were invested into R&D.